Lantheus HoldingsLNTH -1.78%82 Days Payable is 27.67 as of Mar. 2026, which is 8% below its 10-year median of 30.11. GuruFocus rates LNTH with a GF Score™ of 82/100 and a GF Value™ of $90.85 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Lantheus Holdings ranks worse than 90.78% on this metric.
The historical rank and industry rank for Lantheus Holdings's Days Payable or its related term are showing as below:
LNTH'
s Days Payable Range Over the Past 10 Years
Min: 19.2 Med: 30.11 Max: 39.26
Current: 28.77
During the past 13 years, Lantheus Holdings's highest Days Payable was 39.26. The lowest was 19.20. And the median was 30.11.
LNTH's Days Payable is ranked worse than 90.78% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs LNTH: 28.77
Lantheus Holdings's Days Payable
increased
from Mar. 2025 (26.83) to Mar. 2026 (27.67).
It may suggest that Lantheus Holdingsdelayed paying its suppliers.
Lantheus Holdings Days Payable Related Terms
Lantheus Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lantheus Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Days Payable of 27.67 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lantheus Holdings and its competitors. This is near median its historical median of 30.11. Over the past decade, Lantheus Holdings' Days Payable has ranged from 19.20 to 39.26. According to the industry distribution chart, Lantheus Holdings ranks #837 out of 922 companies in the Drug Manufacturers industry, placing it in the top 90.8%.
Is Lantheus Holdings' Days Payable too high?
Lantheus Holdings' current Days Payable of 27.67 is near median its 10-year median of 30.11. Over the past 10 years, this metric has ranged from a low of 19.20 to a high of 39.26. The Drug Manufacturers industry median Days Payable is 90.84. Lantheus Holdings' value of 27.67 is 69.5% below this industry median. Based on the distribution chart, Lantheus Holdings ranks #837 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Days Payable compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #837 out of 922 companies for Days Payable. This places Lantheus Holdings in the lower half of its industry. The industry median Days Payable is 90.84. Lantheus Holdings' value of 27.67 is 69.5% below this benchmark. Historically, Lantheus Holdings' own Days Payable has ranged from 19.20 to 39.26 over the past decade. While the company's 10-year median is 30.11 vs. the industry median of 90.84, Lantheus Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Days Payable of 27.67 is 69.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Days Payable is 27.67, which is near median its own 10-year median of 30.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.85, compared to a current price of $108.93 — trading 19.9% above its estimated fair value. The current Days Payable is 27.67, which is near median its 10-year median of 30.11 and 69.5% below the Drug Manufacturers industry median of 90.84. Lantheus Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Days Payable is 27.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $108.93 is trading 19.9% above its estimated GF Value™ of $90.85.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
Days Payable: 27.67 (near median its 10-year median of 30.11)
GF Value™: $90.85 vs. price of $108.93 (19.9% above fair value)
Industry Position: 69.5% below the Drug Manufacturers median (#837 of 922)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score
Get the complete analysis for LNTH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
